reports
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in ...
TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May 31, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting. Presentations are now public and can be viewed using the below links. Lin...
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences
Avadel Pharmaceuticals to Present at Upcoming Investor Conferences DUBLIN, May 30, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that members of management will participate in the following upcoming investor conferences: Jefferies Global Healthcare Conference: Fireside chat on Thursday, June 6 at 10:30 a.m. ET.Goldman Sachs 45th Annual Global Healthcare Conference: Fireside chat on Wednesday, June 12 at 3:20 p.m. ET. A live webcast of these events, as well as archi...
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUM...
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting NEW YORK, May 28, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming presentations highlighting study designs for post-marketing studies being undertaken for BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 29 – June 1, 2024, in Nas...
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extende...
Avadel Pharmaceuticals Shares New LUMRYZ™ (sodium oxybate) For Extended-release Oral Suspension (CIII) Data at SLEEP 2024 – 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today it will present 11 posters, and one oral presentation, supporting the use of LUMRYZ as a narcole...
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Dire...
Avadel Pharmaceuticals Appoints Naseem Amin, M.D. to its Board of Directors DUBLIN, Ireland, May 21, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today the appointment of Naseem Amin, M.D. to its board of directors, effective May 17, 2024. Dr. Amin, a highly successful executive who brings global industry and leadership experience to Avadel, currently serves as Chief Executive Officer of Orphalan SA. “On behalf of the entire Avadel team, we are excited to welcome Dr. Amin to...
Full House Resorts Announces First Quarter Results
Full House Resorts Announces First Quarter Results - Revenues Increased 39.6% to $69.9 Million in the First Quarter of 2024 - American Place Casino Celebrates Its First Anniversary With Strong Performance Gains - Chamonix Casino Hotel Continued Its Phased Opening, With Its Remaining Hotel Rooms Brought Online During the First Quarter, While Its High-End Steakhouse, 980 Prime, Opened in April LAS VEGAS, May 08, 2024 (GLOBE NEWSWIRE) -- Full House Resorts, Inc. (Nasdaq: FLL) today announced results for the first quarter ended March 31, 2024. On a consolidated basis, revenues in ...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Qua...
Avadel Pharmaceuticals Provides Corporate Update and Reports First Quarter 2024 Financial Results -- Generated $27.2 million in net revenue from sales of LUMRYZ™ -- -- Through March 31, greater than 2,800 patients enrolled in Avadel’s RYZUP patient support services and more than 1,700 patients initiated therapy -- -- Pursuing expansion opportunities for LUMRYZ with sNDA in pediatric narcolepsy; on track to enroll first patient in a Phase 3 pivotal idiopathic hypersomnia trial in the second half of 2024 -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, ...
Inter Parfums, Inc. Reports 2024 First Quarter Results
NEW YORK--(BUSINESS WIRE)-- Inter Parfums, Inc. (NASDAQ GS: IPAR) today reported results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights: ($ in millions, except per share amounts) Three Months Ended March 31, 2024 2023 % Change Net Sales $324 $312 4% Gross Margin 62.5% 65.1% (260 bps) Operating Income $68 $90 (25%) Operating Margin 21.0% 29.0% (800 bps) Net Income attributable to IP $41 $54 (24%) ...
Bioventus Reports First Quarter Financial Results
Bioventus Reports First Quarter Financial Results Raises Full-Year 2024 Financial Guidance Reflecting Enhanced Revenue Growth and Strong Execution of Strategic PrioritiesAccelerated First Quarter Revenue Growth by 8.7%, Organic Growth* by 15.3%Gross Margin Expanded 620 bps and Adjusted Gross Margin* 190 bps DURHAM, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today reported financial results for the three months ended March 30, 2024. “We are pleased with the strong start to the year...
RGC Resources, Inc. Declares Quarterly Dividend
RGC Resources, Inc. Declares Quarterly Dividend ROANOKE, Va., May 02, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (NASDAQ: RGCO), at its meeting on May 1, 2024, declared a quarterly dividend of $0.20 per share on the Company’s common stock. The dividend will be paid on August 1, 2024 to shareholders of record on July 17, 2024. This is the Company’s 321st consecutive quarterly cash dividend. RGC Resources, Inc. provides energy and related products and services to customers in Virginia through its operating subsidiaries including Roanoke Gas Company and RGC Mid...
RGC Resources, Inc. Reports Second Quarter Earnings
RGC Resources, Inc. Reports Second Quarter Earnings ROANOKE, Va., May 01, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (NASDAQ: RGCO) announced consolidated Company earnings of $6,443,390, or $0.63 per share, for the second quarter ended March 31, 2024, compared to $6,341,886, or $0.64 per share, for the fiscal quarter ended March 31, 2023. The increase over the quarter a year ago included $1.2 million in earnings from the Company’s investment in the Mountain Valley Pipeline, LLC (“MVP”), as well as improved utility margins which inflationary cost increases largely offset. Continued in...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First ...
Avadel Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 8 DUBLIN, Ireland, May 01, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, May 8, 2024, to provide a corporate update and discuss the Company's financial results for the first quarter ended March 31, 2024. To access the conference call, investors are invited to dial +1 (800) 715-9871 ...
TG Therapeutics Provides Business Update and Reports First Quarter 202...
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results First quarter 2024 BRIUMVI U.S. net revenue of $50.5 million, representing >25% quarter over quarter growth Total revenue for Q1 2024 of $63.5 million, including a $12.5 million milestone payment for BRIUMVI launch in first EU country New BRIUMVI prescriptions to the TG hub of over 1,250 for Q1 2024, representing >25% growth quarter over quarter Conference call to be held today, May 1, 2024, at 8:30 AM ET NEW YORK, May 01, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Compan...
TG Therapeutics to Host Conference Call on First Quarter 2024 Financia...
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update Conference call to be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held tomorrow, Wednesday, May 1, 2024, at 8:30 AM ET to discuss results for the first quarter of 2024 and provide a business outlook for 2024. Michael S. Weiss, Chairman and Chief Executive Officer, will host the call. In order to participate in the conference call, please call 1-877-40...
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Result...
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024 DURHAM, N.C., April 29, 2024 (GLOBE NEWSWIRE) -- a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2024 before the market opens on Tuesday, May 7, 2024. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A liv...
RGC Resources, Inc. Schedules Second Quarter 2024 Earnings Call
RGC Resources, Inc. Schedules Second Quarter 2024 Earnings Call ROANOKE, Va., April 25, 2024 (GLOBE NEWSWIRE) -- RGC Resources, Inc. (NASDAQ: RGCO) will host its quarterly conference call and webcast to review the results of its fiscal second quarter 2024 on Monday, May 6, 2024 at 9:00 a.m. eastern time. Related presentation materials will be available before the call on the Company website on the Investor & Financial Information page at . Interested parties may access the conference call by dialing toll-free 1-877-304-9269 and entering conference identification number 917621. An archi...
Inter Parfums, Inc. Reports Record 2024 First Quarter Net Sales
NEW YORK--(BUSINESS WIRE)-- Inter Parfums, Inc. (NASDAQ GS: IPAR) (“Inter Parfums” or the “Company”) today announced that for the three months ended March 31, 2024, net sales rose to $324 million, up 4% from $312 million, in the first quarter of 2023. Net Sales: ($ in millions; data may not foot due to rounding) Three Months Ended March 31, 2024 2023 % Change Total Inter Parfums, Inc. $324 $312 4% European based product sales $231 $230 flat United States based product sales $96 ...
Inter Parfums, Inc. Schedules 2024 First Quarter Results
NEW YORK--(BUSINESS WIRE)-- Inter Parfums, Inc. (NASDAQ GS: IPAR) today announced that it will issue financial results for the three months ended March 31, 2024, on Tuesday, May 7, 2024, after the close of the stock market. Management will host a conference call to discuss financial results and business operations beginning at 11:00 am ET on Wednesday, May 8, 2024. Interested parties may participate in the live call by dialing: U.S. / Toll-free: (877) 423-9820 International: (201) 493-6749 Participants are asked to dial-in approximately 10 minutes before th...
Full House Resorts Announces First Quarter Earnings Release Date
Full House Resorts Announces First Quarter Earnings Release Date LAS VEGAS, April 22, 2024 (GLOBE NEWSWIRE) -- Full House Resorts (NASDAQ: FLL) announced today that it will report its first quarter 2024 financial results on Wednesday, May 8, 2024, followed by a conference call at 4:30 p.m. ET (1:30 p.m. PT). Investors can access the live audio webcast from the Company’s website at under the investor relations section. The conference call can also be accessed by dialing (201) 689-8470. A replay of the conference call will be available shortly after the conclusion of the call through May ...
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (...
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two additional data presentations from the ULTIMATE I & II Phase 3 trials evaluating BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the 2024 American Academy of Neurology (AAN) annual meeting, being held in Denver, Colorado. Links to the data presented yesterday are included below. ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.